B.M.K. Donato

Patrones de Tratamiento y Costo de Atención del Cáncer de Mama Avanzado Con Falla a Antraciclinas y Taxanos en 3 Hospitales Públicos de México

OBJECTIVES In Mexico, breast cancer is the second leading cause of cancer mortality among females. For patients with advanced breast cancer (ABC) resistant to anthracyclines and taxanes (AT), there are limited treatment options. There is a scarcity of data regarding clinical management of this population and treatment costs at this stage of the disease. The objective of this study was to describe the treatment patterns of care for metastatic breast cancer after AT and the associated cost from the point-of-view of the Mexican Public Health Care Sector. METHODS Between January 1, 2004 and December 31, 2007, a retrospective cohort of adult female ABC patients resistant to AT was developed by reviewing and extracting key data from medical charts. We conducted a retrospective, transversal and descriptive analysis of the patient data. Target population data files were obtained from 414 patients from 3 public hospitals in México. RESULTS Capecitabine, vinorelbine and cyclophosphamide were the most commonly prescribed agents, however clinical drug therapy management of the disease was different within and among the three hospitals included in the study. This difference translated into a disparity of prescription costs, ranging from an average of

Treatment Patterns and Health Resource Utilization Among Atrial Fibrillation Patients in United Arab Emirates and Saudi Arabia

122.22 pesos/patient/month (cyclophosphamide, IC 95%

Estimation of the effectiveness of apixaban in non valvular atrial fibrillation in anticoagulant suitable population in Argentina

94.43-

Abstract W P147: Apixaban Versus Warfarin in Patients with Atrial Fibrillation: Patient Characteristics of the Latin America Cohort from a Multinational Clinical Trial

150.01) to

Glycemic, Lipid, and Blood Pressure Control Among Individuals with Type 2 Diabetes Mellitus in Saudi Arabia.

37,835.53 pesos/patient/month (capecitabine+trastuzumab IC 95%

Treatment Patterns Among Type 2 Diabetes Mellitus Patients in Saudi Arabia.

34,953.18-

The Epidemiologic Burden of Hepatitis C Virus Infection in Egypt

40,717.88) for the first treatment after AT. CONCLUSIONS The results highlight a lack of standardized care for patients and suggest that differences in treatment patterns are not only a reflection of scarcity of scientific data and diversity of prescription preferences among physicians but also of economic restrictions. Ultimately, there is a clear unmet medical need to be addressed through evidence-based medicine alternatives that support efficacy and cost effectiveness treatments.

Cost Consequence Analysis Of Apixaban Versus Warfarin In Patients With Atrial Fibrillation In The Mexican Public Health Sector

normalized ratio (INR) monitoring in patients on vitamin K antagonists (VKA) on maintenance anticoagulation. Methods: This interim analysis is based on data of 2863 patients enrolled in the PREFER in VTE registry in 7 Western European countries (France, Germany, Italy, Spain, UK, Austria and Switzerland). 1689 had DVT (only) and 1174 had PE (±DVT). Results: At 6-month follow-up, 51.5% of the patients were treated with VKA. INR measurements at 6-month follow-up (UK: 3 month) were performed in the hospital setting for 13.1% of these patients (most frequently in Spain 42.9%, UK 32.7%,, Italy 18.0%), in the anticoagulation center in 23.6% (in Spain 40.0%, Italy 37.0%, UK 16.4%), in the physician’s office in 16.8% (Germany 90.7%, UK 41.8%), by the patient self-measured in 4.9% (Spain 8.6%), or at biology labs or other institutions in 36.9% (France 92.4%). The patient’s mean travel distance to the INR site was 5.8 ±9.16 km overall, the range was 0-90 km (mean varied across countries from 2.4 to 7.7 km). Mean travel time was 14.3 ±18.4 min (across countries 5.7 to 18.2 min). Patients most frequently used their private car/motorbike (50.8 %) or walked (16.4%). The mean number of INR measurements over the 6-month period was 16.8, the number of INR measurements per month was 2.8 ±1.2 overall (across countries 1.8 to 3.2). ConClusions: In the various countries, different institutions are responsible for routine INR measurements. While biology labs are almost exclusively used in France, there is no equivalent for such institutions in other countries. INR self-measurement plays a minor role. Patients usually have the INR sites in their vicinity, and the average number of measurements shows little variation between countries.